Atezolizumab generates excitement in advanced urothelial cancer

When patients were stratified by prognostic factors, the overall response rate was highest, at 23%, among those with lymph nodes as the only site of metastases.

Median progression-free survival was 2.1 months in the entire cohort and also regardless of PD-L1 staining. Median overall survival was 7.9 months in the entire cohort; it was longer for patients with high staining (11.4 months) than for peers with intermediate or low staining (6.7 months).

The 12-month overall survival rate was 36% for the entire cohort, 30% for patients with low or intermediate staining, and 48% for patients with high staining.

“Considering 12-month overall survival estimates for second-line chemo are approximately 20%, these data are truly exciting,” Dr. Hoffman-Censits said.

Analysis of adverse events showed that atezolizumab had a favorable safety profile. In particular, there were no immune-mediated adverse events deemed to be related to treatment.